Besides, our previous proteomic research indicated that CTGF expression in FLS from RA patients was remarkably higher than that in the controls [4], and the clinical results revealed that CTGF could be used as a biomarker for the diagnosis of RA. This evidence concerns the gene CCN2 and rheumatoid arthritis.